Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 199) Show all publications
Gillett, D., Senanayake, R., MacFarlane, J., Bashari, W., Palma, A., Hu, L., . . . Gurnell, M. (2025). A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism. Journal of Nuclear Medicine, 66(3), 434-440
Open this publication in new window or tab >>A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism
Show others...
2025 (English)In: Journal of Nuclear Medicine, ISSN 0161-5505, E-ISSN 1535-5667, Vol. 66, no 3, p. 434-440Article in journal (Refereed) Published
Abstract [en]

Primary aldosteronism (PA) is a common, potentially reversible, cause of hypertension. Distinguishing unilateral from bilateral PA is critical when deciding who should be offered surgery (unilateral adrenalectomy). Recent studies have shown that PET/CT with [11C]metomidate can accurately identify unilateral PA, with localization of the causative aldosterone-producing adenoma (APA). However, the availability of [11C]metomidate is limited to centers with an on-site cyclotron. Here, we report an early-phase human study with the 18F-labeled analog, para-chloro-2-[18F]fluoroethyletomidate ([18F]CETO).

Methods: We conducted a phase I/IIa, single-center, open-label, microdosing study. The primary objective was to evaluate the safety of up to 2 administrations of [18F]CETO in 6 patients with PA (3 unilateral disease, 3 bilateral disease) and 5 healthy volunteers. Safety evaluation included assessment of adrenal function after the first [18F]CETO administration. The biodistribution of [18F]CETO was assessed in a 90-min dynamic PET acquisition. In patients with PA, the effect of pretreatment with oral dexamethasone on [18F]CETO uptake by normal adrenal tissue and APAs was also assessed.

Results: Eleven participants were recruited to the trial, including 6 patients and 5 healthy volunteers. No subjects experienced serious adverse events or reactions, and all participants had normal adrenal function after [18F]CETO administration. [18F]CETO demonstrated high selectivity for the adrenal glands with low uptake in other tissues. Visualization of APAs was enhanced after dexamethasone pretreatment, which suppressed [18F]CETO uptake by normal adrenal tissue.

Conclusion: [18F]CETO is a safe radiopharmaceutical for PET imaging of the adrenal glands, with no observed adverse reactions or impairment of adrenal function in this study. [18F]CETO demonstrates selective high affinity for adrenal tissue, particularly APAs. Distinction between APAs and normal adrenal tissue is enhanced by dexamethasone pretreatment to suppress [18F]CETO uptake by normal glands. This positions [18F]CETO as a promising imaging tool for evaluation in the context of PA.

Place, publisher, year, edition, pages
Society of Nuclear Medicine, 2025
Keywords
PET, [18F]CETO, molecular imaging, primary aldosteronism
National Category
Radiology and Medical Imaging Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-556033 (URN)10.2967/jnumed.124.268425 (DOI)001470417200019 ()39884776 (PubMedID)2-s2.0-86000673628 (Scopus ID)
Available from: 2025-05-08 Created: 2025-05-08 Last updated: 2025-05-08Bibliographically approved
Klimàcek, B., Åkerström, T., Annebäck, M., Hellman, P., Norlén, O. & Stålberg, P. (2025). Evaluation of hand-assisted laparoscopic surgery of small intestinal neuroendocrine tumours as an alternative surgical treatment to open surgery. Langenbeck's archives of surgery (Print), 410(1), Article ID 90.
Open this publication in new window or tab >>Evaluation of hand-assisted laparoscopic surgery of small intestinal neuroendocrine tumours as an alternative surgical treatment to open surgery
Show others...
2025 (English)In: Langenbeck's archives of surgery (Print), ISSN 1435-2443, E-ISSN 1435-2451, Vol. 410, no 1, article id 90Article in journal (Refereed) Published
Abstract [en]

Purpose Small intestinal neuroendocrine tumours (SI-NETs) are the most common malignancy of the small bowel. Curative treatment is surgical, with exploratory laparotomy considered the standard approach. This study aimed to assess the outcomes of minimally invasive surgery compared to open approach for SI-NETs at the Endocrine surgical unit at Uppsala University Hospital. Methods This retrospective cohort study included patients who underwent surgery for SI-NET between 2013 and 2023 at Uppsala University Hospital. Variables such as operative time, length of hospital stay, use of analgesia and radicality were compared between groups of patients operated on before and after 2019, when hand-port assisted laparoscopic surgery (HALS) for SI-NETs was introduced at our unit. Outcomes were further compared between open and hand-port assisted laparoscopic approaches. The primary outcome was the rate of radicality achieved for stage II-III patients. Secondary outcomes included operative time, the length of hospital stay and the use of epidural and patient-controlled analgesia. Results Of 97 patients, 58 (59.8%) underwent open surgery and 39 (40.2%) underwent hand-port assisted laparoscopic surgery. There was no significant difference in operative time (121 min [91.3-150.3] vs 108 min [83-141]), length of hospital stay, 6 days [4-7] vs 5 days [4-8]), and surgical radicality in patients with stage II-III, 85.2% vs 100%, (p = 0.079). 86.2% of patients with explorative laparotomy required epidural analgesia compared to only 23.1% with HALS (p < 0.001). Conclusion Hand-port assisted laparoscopic surgery of SI-NETs is a feasible approach that preserves radical resection while enhancing postoperative recovery, with a lower requirement of epidural analgesia.

Place, publisher, year, edition, pages
Springer Nature, 2025
Keywords
Hand-assisted laparoscopic surgery, Small intestinal neuroendocrine tumours, Open surgery, Radicality, Minimally invasive surgery
National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-553121 (URN)10.1007/s00423-025-03658-z (DOI)001439675400001 ()40047926 (PubMedID)2-s2.0-86000287810 (Scopus ID)
Funder
Swedish Cancer Society
Available from: 2025-03-26 Created: 2025-03-26 Last updated: 2025-03-26Bibliographically approved
Makhnov, N., Skov, J., Åkerström, T., Axling, F., Andernord, D., Bergenheim, M., . . . Hellman, P. (2025). Screening For Primary Aldosteronism In 1,181 Swedish Primary Care Patients With Hypertension. Frontiers in Endocrinology, 16, Article ID 1555572.
Open this publication in new window or tab >>Screening For Primary Aldosteronism In 1,181 Swedish Primary Care Patients With Hypertension
Show others...
2025 (English)In: Frontiers in Endocrinology, E-ISSN 1664-2392, Vol. 16, article id 1555572Article in journal (Refereed) Published
Abstract [en]

Objective: Primary aldosteronism (PA) is a common cause of hypertension. It entails elevated morbidity and mortality that do not sufficiently improve with conventional antihypertensive therapy. Screening for PA by plasma aldosterone–renin ratio (ARR) enables discovery and specific treatment of affected patients. By screening primary care patients with hypertension and evaluating them further according to the Endocrine Society guidelines, we aimed to assess the prevalence of PA, the factors affecting biochemical diagnostics, and the outcome of lateralization studies and of specific treatment of the discovered PA cases.

Design, patients, and methods: Prospective evaluation of screening for PA was conducted in 1,181 patients. Screening by ARR was performed under current therapy, but without mineralocorticoid receptor antagonists (MRA), under normokalemia, and confirmed by the intravenous saline suppression test, SST#1. Those with results in a defined gray zone underwent therapy adjustment and then completed SST#2. Plasma aldosterone and ARR were compared under different stages of the diagnostic process. All patients with PA were offered adrenal venous sampling, or, in certain cases, adrenocortical-specific positron emission tomography. Lateralizing cases were offered laparoscopic adrenalectomy. Patients with bilateral disease were treated with MRA. Treatment results were assessed after a minimum of 6 months.

Results: A total of 53 discovered cases of (mostly mild) PA corresponded to its prevalence of 4.5%. Initial seated ARR was higher than recumbent ARR before SST#1. At SST#2, initial ARR and final aldosterone were higher than at SST#1. Localizing studies (accepted by 45 patients) found 14 lateralized cases. Of the 11 operated cases, 4 had aldosterone-producing adenoma, and the remainder had micro- and macronodular histopathology. A total of 31 patients had bilateral PA. Both surgical and conservative treatments were well tolerated and led to improved blood pressure and higher renin, indicating risk amelioration.

Conclusions: PA is prevalent among primary care patients with hypertension and can be screened for under current antihypertensive therapy. Aldosterone-producing adenoma was rare in this cohort. The study results support active screening of primary care patients with hypertension for PA in order to offer appropriate treatment options.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2025
Keywords
primary aldosteronism, screening, hypertension, outpatients, aldosterone, renin, therapeutics
National Category
Surgery Endocrinology and Diabetes
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-554033 (URN)10.3389/fendo.2025.1555572 (DOI)001476399600001 ()40297172 (PubMedID)2-s2.0-105003811480 (Scopus ID)
Funder
Sjukvårdsregionala forskningsrådet Mellansverige, 651241Sjukvårdsregionala forskningsrådet Mellansverige, 842171Sjukvårdsregionala forskningsrådet Mellansverige, 930708Region Värmland, 637541Region Värmland, 741191Region Värmland, 840631Region Värmland, 930327Region Värmland, 939850Region Värmland, 967684Region Värmland, 980171Region Värmland, 993231
Available from: 2025-04-05 Created: 2025-04-05 Last updated: 2025-05-09Bibliographically approved
Makhnov, N., Axling, F., Barazeghi, E., Stålberg, P., Åkerström, T. & Hellman, P. (2025). Serum microRNAs as peripheral markers of primary aldosteronism. Frontiers in Endocrinology
Open this publication in new window or tab >>Serum microRNAs as peripheral markers of primary aldosteronism
Show others...
2025 (English)In: Frontiers in Endocrinology, E-ISSN 1664-2392Article in journal (Refereed) Published
Abstract [en]

Background: Primary aldosteronism (PA) is the principal cause of secondaryhypertension; it leads to significantly elevated cardiovascular morbidity andmortality, but only a fraction of its cases ever get detected, partially due todiagnostic procedures that are difficult to perform and to interpret. Morestraightforward diagnostic methods are needed. Lateralized, or unilateral PA(uPA), is best treated by surgery. Bilateral PA (bPA) is treated medically.Aim: The aim of our study was to explore microRNA (miRNA) in peripheral bloodas markers of PA, uPA and bPA.

Methods: In groups of subjects with primary hypertension (HT, n = 11), bPA (n =12), and uPA (n = 16), peripheral serum was used for isolation of total RNA, librarypreparation, and NGS sequencing to achieve a comparative analysis of miRNAexpression. Five-fold cross-validation support vector machine learning (ML)models were employed to search for miRNA that could be used as markers ofPA and its forms.

Results: In our cohort of patients, the discovered combinations of miRNAs could,with a high level of accuracy, sensitivity, and specificity, characterize thedifference between HT and PA, as well as between a combined group of HT +bPA vs. uPA. The differentiating parameters were moderately good forcomparison of bPA vs. uPA.

Conclusion: Within our patient cohort, and using ML, the study identifieddistinctly different miRNA profiles between HT and PA, as well as between bPAand uPA. Further validation studies may lead to the emergence of a new tool forclinical diagnostics of PA.

Place, publisher, year, edition, pages
Lausanne: Frontiers Media S.A., 2025
National Category
Surgery
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-553580 (URN)10.3389/fendo.2025.1511096 (DOI)001457813300001 ()40182638 (PubMedID)2-s2.0-105001691132 (Scopus ID)
Available from: 2025-03-28 Created: 2025-03-28 Last updated: 2025-04-24Bibliographically approved
Vyakaranam, A. R., Mahamed, M. M., Hellman, P., Eriksson, O., Espes, D., Christoffersson, G. & Sundin, A. (2024). Non-invasive imaging of sympathetic innervation of the pancreas in individuals with type 2 diabetes. Diabetologia, 67(1), 199-208
Open this publication in new window or tab >>Non-invasive imaging of sympathetic innervation of the pancreas in individuals with type 2 diabetes
Show others...
2024 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 67, no 1, p. 199-208Article in journal (Refereed) Published
Abstract [en]

Aims/hypothesis

Compromised pancreatic sympathetic innervation has been suggested as a factor involved in both immune-mediated beta cell destruction and endocrine dysregulation of pancreatic islets. To further explore these intriguing findings, new techniques for in vivo assessment of pancreatic innervation are required. This is a retrospective study that aimed to investigate whether the noradrenaline (norepinephrine) analogue 11C-hydroxy ephedrine (11C-HED) could be used for quantitative positron emission tomography (PET) imaging of the sympathetic innervation of the human pancreas.

Methods

In 25 individuals with type 2 diabetes and 64 individuals without diabetes, all of whom had previously undergone 11C-HED-PET/CT because of pheochromocytoma or paraganglioma (or suspicion thereof), the 11C-HED standardised uptake value (SUVmean), 11C-HED specific binding index (SBI), pancreatic functional volume (FV, in ml), functional neuronal volume (FNV, calculated as SUVmean × FV), specific binding index with functional volume (SBI FV, calculated as SBI × FV) and attenuation on CT (HU) were investigated in the entire pancreas, and additionally in six separate anatomical pancreatic regions.

Results

Generally, 11C-HED uptake in the pancreas was high, with marked individual variation, suggesting variability in sympathetic innervation. Moreover, pancreatic CT attenuation (HU) (p<0.001), 11C-HED SBI (p=0.0049) and SBI FV (p=0.0142) were lower in individuals with type 2 diabetes than in individuals without diabetes, whereas 11C-HED SUVmean (p=0.15), FV (p=0.73) and FNV (p=0.30) were similar.

Conclusions/interpretation

We demonstrate the feasibility of using 11C-HED-PET for non-invasive assessment of pancreatic sympathetic innervation in humans. These findings warrant further prospective evaluation, especially in individuals with theoretical defects in pancreatic sympathetic innervation, such as those with type 1 diabetes.

Place, publisher, year, edition, pages
Springer, 2024
Keywords
11C-HED, 11C-hydroxy ephedrine, A41, Diabetes, Innervation, PET-CT specific binding index
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-498362 (URN)10.1007/s00125-023-06039-7 (DOI)001101045200001 ()37935826 (PubMedID)
Funder
Uppsala UniversityScience for Life Laboratory, SciLifeLabSwedish Research Council, 2018-02314Swedish Research Council, 2020-02312Ernfors FoundationNils Erik Holmstens forskningsstiftelseEXODIAB - Excellence of Diabetes Research in SwedenSwedish Child Diabetes FoundationDiabetesfondenInsamlingsstiftelsen Diabetes Wellness, 2409-PG
Available from: 2023-03-15 Created: 2023-03-15 Last updated: 2024-11-21Bibliographically approved
Silins, I., Moreno, A., Wall, A., Aigbirhio, F., Gurnell, M., Brown, M., . . . Lubberink, M. (2024). Radiation dosimetry of para-chloro-2-[18F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging. EJNMMI Research, 14(1), Article ID 48.
Open this publication in new window or tab >>Radiation dosimetry of para-chloro-2-[18F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging
Show others...
2024 (English)In: EJNMMI Research, E-ISSN 2191-219X, Vol. 14, no 1, article id 48Article in journal (Refereed) Published
Abstract [en]

Background [C-11]metomidate, a methyl ester analogue of etomidate, is used for positron emission tomography of adrenocortical cancer, and has been tested in recent clinical trials for lateralization in primary aldosteronism (PA). However, in PA, visualization as well as uptake quantification are hampered by the tracer's rather high non-specific liver uptake, and its overall clinical usefulness is also limited by the short 20-minute half-life of carbon-11. Therefore, we evaluated para-chloro-2-[F-18]fluoroethyl-etomidate, [F-18]CETO, a fluorine-18 (T-1/2=109.8 min) analogue, as a potential new adrenocortical PET tracer. The aim of this study was to assess radiation dosimetry of [F-18]CETO. Results [F-18]CETO showed a high uptake in adrenal glands, still increasing at 5 h post injection. Adrenal glands (absorbed dose coefficients 0.100 +/- 0.032 mGy/MBq in males and 0.124 +/- 0.013 mGy/MBq in females) received the highest absorbed dose. The effective dose coefficient was 20 mu Sv/MBq. Conclusions[F-18]CETO has a favourable biodistribution in humans for adrenal imaging. The effective dose for a typical clinical PET examination with 200 MBq [F-18]CETO is 4 mSv. Trial registration ClinicalTrials.gov, NCT05361083 Retrospectively registered 29 April 2022. at, URL: https://clinicaltrials.gov/ct2/show/NCT05361083.

Place, publisher, year, edition, pages
SPRINGER, 2024
Keywords
[F-18]CETO, Positron emission tomography, Primary aldosteronism, Adrenal, Tumour, Adenoma, Conn adenoma
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-541020 (URN)10.1186/s13550-024-01109-2 (DOI)001228902800001 ()38771379 (PubMedID)
Available from: 2025-02-12 Created: 2025-02-12 Last updated: 2025-02-12Bibliographically approved
Backman, S., Botling, J., Nord, H., Ghosal, S., Stålberg, P., Juhlin, C. C., . . . Crona, J. (2024). The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation. Journal of Pathology, 264(4), 357-370
Open this publication in new window or tab >>The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation
Show others...
2024 (English)In: Journal of Pathology, ISSN 0022-3417, E-ISSN 1096-9896, Vol. 264, no 4, p. 357-370Article in journal (Refereed) Published
Abstract [en]

Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular may progress from a low/intermediate to a high-grade disease. The aim of this work was to understand the molecular mechanisms underlying metastatic progression as well as PanNET transformation from a low/intermediate to a high-grade disease. We performed multi-omics analysis (genome/exome sequencing, total RNA-sequencing and methylation array) of 32 longitudinal samples from six patients with metastatic low/intermediate grade PanNET. The clonal composition of tumour lesions and underlying phylogeny of each patient were determined with bioinformatics analyses. Findings were validated in post-alkylating chemotherapy samples from 24 patients with PanNET using targeted next generation sequencing. We validate the current PanNET evolutionary model with MEN1 inactivation that occurs very early in tumourigenesis. This was followed by pronounced genetic diversity on both spatial and temporal levels, with parallel and convergent tumour evolution involving the ATRX/DAXX and mechanistic target of the rapamycin (mTOR) pathways. Following alkylating chemotherapy treatment, some PanNETs developed mismatch repair deficiency and acquired a hypermutational phenotype. This was validated among 16 patients with PanNET who had high-grade progression after alkylating chemotherapy, of whom eight had a tumour mutational burden >50 (50%). In comparison, among the eight patients who did not show high-grade progression, 0 had a tumour mutational burden >50 (0%; odds ratio ‘infinite’, 95% confidence interval 1.8 to ‘infinite’, p = 0.02). Our findings contribute to broaden the understanding of metastatic/high-grade PanNETs and suggests that therapy driven disease evolution is an important hallmark of this disease.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
neuroendocrine tumours, tumour evolution, heterogeneity, multi-omics, pancreas, metastasis, mismatch repair, alkylating chemotherapy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-523490 (URN)10.1002/path.6348 (DOI)001327034800001 ()38313278 (PubMedID)2-s2.0-85205548822 (Scopus ID)
Funder
Swedish Research Council, 2022-06725Swedish Cancer SocietyInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroÅke Wiberg Foundation
Available from: 2024-02-19 Created: 2024-02-19 Last updated: 2025-01-30Bibliographically approved
Kjaer, J., Norlén, O., Hellman, P. & Stålberg, P. (2023). Author's Reply: Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation [Letter to the editor]. World Journal of Surgery, 47(4), 1084-1085
Open this publication in new window or tab >>Author's Reply: Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation
2023 (English)In: World Journal of Surgery, ISSN 0364-2313, E-ISSN 1432-2323, Vol. 47, no 4, p. 1084-1085Article in journal, Letter (Other academic) Published
Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-502358 (URN)10.1007/s00268-023-06916-7 (DOI)000923116400001 ()36705741 (PubMedID)
Note

Peter Stålberg is noted as Peter Stalberg in the publication list of authors

Correction in: World Journal of Surgery, vol. 47, page 1086, DOI: 10.1007/s00268-023-06938-1

Available from: 2023-05-31 Created: 2023-05-31 Last updated: 2023-05-31Bibliographically approved
Silins, I., Sundin, A., Lubberink, M., O'Sullivan, L., Gurnell, M., Aigbirhio, F., . . . Antoni, G. (2023). First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours. European Journal of Nuclear Medicine and Molecular Imaging, 50(2), 398-409
Open this publication in new window or tab >>First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours
Show others...
2023 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 50, no 2, p. 398-409Article in journal (Refereed) Published
Abstract [en]

Purpose

[11C]Metomidate positron emission tomography (PET) is currently used for staging of adrenocortical carcinoma and for lateralization in primary aldosteronism (PA). Due to the short half-life of carbon-11 and a high non-specific liver uptake of [11C]metomidate there is a need for improved adrenal imaging methods. In a previous pre-clinical study para-chloro-2-[18F]fluoroethyletomidate has been proven to be a specific adrenal tracer. The objective is to perform a first evaluation of para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-PET/CT) in patients with adrenal tumours and healthy volunteers.

Methods

Fifteen patients underwent [18F]CETO-PET/CT. Five healthy volunteers were recruited for test-retest analysis and three out of the five underwent additional [15O]water PET/CT to measure adrenal blood flow. Arterial blood sampling and tracer metabolite analysis was performed. The kinetics of [18F]CETO were assessed and simplified quantitative methods were validated by comparison to outcome measures of tracer kinetic analysis.

Results

Uptake of [18F]CETO was low in the liver and high in adrenals. Initial metabolization was rapid, followed by a plateau. The kinetics of [18F]CETO in healthy adrenals and all adrenal pathologies, except for adrenocortical carcinoma, were best described by an irreversible single-tissue compartment model. Standardized uptake values (SUV) correlated well with the uptake rate constant K1. Both K1 and SUV were highly correlated to adrenal blood flow in healthy controls. Repeatability coefficients of K1, SUV65–70, and SUV120 were 25, 22, and 17%.

Conclusions

High adrenal uptake combined with a low unspecific liver uptake suggests that 18F]CETO is a suitable tracer for adrenal imaging. Adrenal SUV, based on a whole-body scan at 1 h p.i., correlated well with the net uptake rate Ki.

Trial registration

ClinicalTrials.gov, NCT05361083 Retrospectively registered 29 April 2022. at, https://clinicaltrials.gov/ct2/show/NCT05361083

Place, publisher, year, edition, pages
Springer Nature, 2023
Keywords
[18F]CETO, Adrenal tracer, Positron emission tomography
National Category
Surgery Radiology, Nuclear Medicine and Medical Imaging
Research subject
Surgery
Identifiers
urn:nbn:se:uu:diva-487613 (URN)10.1007/s00259-022-05957-9 (DOI)000851349100002 ()36074157 (PubMedID)
Funder
Uppsala University
Available from: 2022-10-30 Created: 2022-10-30 Last updated: 2023-01-10Bibliographically approved
Edfeldt, K., Hellman, P., Granberg, D., Lagergren, P., Thiis‐Evensen, E., Sundin, A. & Andersson, C. (2023). Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of neuroendocrinology, 35(10)
Open this publication in new window or tab >>Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours
Show others...
2023 (English)In: Journal of neuroendocrinology, ISSN 0953-8194, E-ISSN 1365-2826, Vol. 35, no 10Article in journal (Refereed) Published
Abstract [en]

Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health-related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression-free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ-C30, and the gastrointestinal NET-specifically EORTC QLQ-GINET21. Patients with NET (n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population (n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person-centred care.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-514352 (URN)10.1111/jne.13342 (DOI)001080947000001 ()
Available from: 2023-10-17 Created: 2023-10-17 Last updated: 2024-04-12Bibliographically approved
Projects
New tools in diagnostics of adrenocortical tumours [2011-03735_VR]; Uppsala UniversityImproved diagnosis and potential treatment targets for primary aldosteronism, with special emphasis on the angiotensin II type 2-receptor. [2015-02860_VR]; Uppsala University
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-5322-5073

Search in DiVA

Show all publications